The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations
Women who carry pathogenic mutations in BRCA1 and BRCA2 have a lifetime risk of developing breast cancer of up to 80%. However, risk estimates vary in part due to genetic modifiers. We investigated the association of the RAD52 S346X variant as a modifier of the risk of developing breast and ovarian...
Main Authors: | Aaron W. Adamson, Yuan Chun Ding, Carlos Mendez‐Dorantes, Adam M. Bailis, Jeremy M. Stark, Susan L. Neuhausen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-06-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12665 |
Similar Items
-
Non-Recombinogenic Functions of Rad51, BRCA2, and Rad52 in DNA Damage Tolerance
by: Félix Prado
Published: (2021-09-01) -
Emerging Roles of RAD52 in Genome Maintenance
by: Manisha Jalan, et al.
Published: (2019-07-01) -
Replication Stress Response Links RAD52 to Protecting Common Fragile Sites
by: Xiaohua Wu
Published: (2019-09-01) -
Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells
by: Wei-Che Tseng, et al.
Published: (2021-04-01) -
Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells
by: Sarah R Hengel, et al.
Published: (2016-07-01)